Pearl Therapeutics, which is developing several inhaled drugs, has announced that it has hired Michael Riebe as VP, Pharmaceutical Development and Research, effective immediately. Riebe, a past chair and current steering committee member of the AAPS Inhalation and Nasal Technology Focus Group, was most recently VP of Research and Development at iCeutica and previously worked in inhaled drug development at Merck and at Glaxo.
Pearl President and CEO Chuck Bramlage said, “Mike’s extensive experience in developing respiratory products through approval and commercialization will be extremely valuable as we move our lead combination bronchodilator for COPD, PT003, and its components, PT005 and PT001 through the final stages of clinical development. In addition, our plans for expanding our pipeline, including the development of a triple drug combination, PT010, will benefit from his broad product development skills. Speaking for the management and board of directors, we welcome Mike to the Pearl team.”
The company recently raised $65 million to initiate Phase 3 studies of PT003.
Read the Pearl Therapeutics press release.
